Amylyx Pharmaceuticals (AMLX) Cash & Equivalents (2021 - 2026)

Amylyx Pharmaceuticals' Cash & Equivalents history runs 6 years deep, the most recent figure standing at $229.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 283.4% year-over-year to $229.1 million; the TTM figure through Mar 2026 stood at $229.1 million (up 283.4% YoY), while the FY2025 annual figure was $226.7 million, up 192.86% from the prior year.
• Cash & Equivalents was $229.1 million for Q1 2026 at Amylyx Pharmaceuticals, up from $226.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $247.8 million in Q2 2023 to a low of $58.1 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $130.0 million across 5 years, with a median of $110.4 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Cash & Equivalents plunged 69.73% in 2024, then soared 283.4% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $62.5 million in 2022, then surged by 172.21% to $170.2 million in 2023, then plunged by 54.53% to $77.4 million in 2024, then jumped by 192.86% to $226.7 million in 2025, then grew by 1.1% to $229.1 million in 2026.
• The last three Cash & Equivalents figures came in at $229.1 million (Q1 2026), $226.7 million (Q4 2025), and $225.2 million (Q3 2025), per Business Quant data.